NGS (Next-Generation Sequencing) is a genomic test that analyzes hundreds of cancer-related genes simultaneously. It identifies mutations, gene fusions, copy number changes, and biomarkers like MSI and TMB — enabling oncologists to select targeted therapies and immunotherapies matched to your specific tumor.

NGS full form is Next-Generation Sequencing. It refers to a group of modern DNA sequencing technologies (including Illumina, SOLiD, and PacBio platforms) that read millions of DNA fragments in parallel, replacing older one-gene-at-a-time sequencing methods.

BigOHealth coordinates NGS testing across India, connecting you with accredited NGS labs for sample collection, sequencing, and expert-reviewed reporting — no matter which city you're in.

NGS is recommended for patients with advanced or metastatic cancer, those who haven't responded to standard chemotherapy, patients with certain cancer types (lung, breast, colorectal, ovarian), and anyone seeking access to targeted therapies or clinical trials.

NGS is especially valuable for lung cancer (EGFR, ALK, ROS1), breast cancer (HER2, BRCA), colorectal cancer (KRAS, NRAS, BRAF), ovarian cancer (BRCA), and hematological cancers. However, NGS adds value across almost all solid tumor types.

Most NGS reports are delivered in 10–21 business days. The process includes sample collection, DNA extraction, sequencing, bioinformatics analysis, and expert report review by a molecular pathologist.

NGS testing in India typically ranges from ₹35,000 to ₹1,20,000 depending on the panel size (targeted vs. comprehensive), lab, and whether liquid biopsy or tissue biopsy is used. Contact us for current pricing.

NGS can be performed on FFPE (formalin-fixed paraffin-embedded) tumor tissue from a biopsy or surgical specimen, or via liquid biopsy using a blood sample to detect circulating tumor DNA (ctDNA).

Both use DNA sequencing, but liquid biopsy analyzes circulating tumor DNA (ctDNA) from a blood sample, while standard NGS uses tumor tissue. Liquid biopsy is less invasive and useful for monitoring treatment response, but may detect fewer mutations than tissue-based NGS.

Yes. Many precision oncology clinical trials require specific genomic alterations detected by NGS. Having an NGS report significantly expands your eligibility for mutation-matched clinical trials across India and globally.

Yes. If you've already been tested, upload your existing NGS report and our molecular oncology team and genetic counselors will review it with you, explain what each finding means, and help you understand your targeted therapy and clinical trial options — no need to repeat the test.

A 'no actionable mutation found' result doesn't mean no options remain. It means your specific panel didn't find an FDA-matched target — but your TMB/MSI status, a broader panel, or re-biopsy at progression may still reveal options. A second opinion from a molecular tumor board can clarify next steps.

In most cases, your existing FFPE tumor block from a prior biopsy or surgery can be used for NGS — a new procedure usually isn't required. If tissue is insufficient or too old, a blood-based liquid biopsy is often a non-invasive alternative.

Your NGS report is reviewed by a molecular pathologist and interpreted in context of your case by an oncologist or genetic counselor, who will explain the findings, actionable mutations, and treatment implications in clear, patient-friendly terms.